Clinical Trial

Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a randomized double-blind placebo-controlled multicenter clinical trial to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell (UC-MSC) transplantation for the treatment of acute-on-chronic liver failure (ACLF). UC-MSC therapy may improve the clinical outcomes of patients with ACLF. The trial would provide scientific evidence for UC-MSC transplantation as a potential treatment for ACLF.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-03; most recent amendment 2024-05-06.
Status change: Not Yet Recruiting → Recruiting 2024-05-06
Trial Details
NCT Number NCT05985863
Lead Sponsor Beijing 302 Hospital
Collaborators: Shulan (Hang Zhou) Hospital, BeijingYouan Hospital, Shenzhen Third People's Hospital, Shen Zhen Wingor Biotechnology CO. LTD
Conditions Acute-On-Chronic Liver Failure
Enrollment 150 participants
Start Date 2023-09-30
Primary Completion 2026-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-05-07